Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system ; volume:14 ; number:1 ; day:13 ; month:9 ; year:2024 ; pages:1-10 ; date:12.2024
Scientific reports ; 14, Heft 1 (13.9.2024), 1-10, 12.2024
- Creator
-
Chen, Yuheng
Ren, Xiayang
Dai, Yuanyuan
Wang, Yanfeng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-71977-0
- URN
-
urn:nbn:de:101:1-2411272117096.706526727081
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Yuheng
- Ren, Xiayang
- Dai, Yuanyuan
- Wang, Yanfeng
- SpringerLink (Online service)
Other Objects (12)
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
The First FDA-Approved Antibody-Drug Conjugate
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
The First FDA-Approved Antibody-Drug Conjugate
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Research progress of antibody–drug conjugates in gynecologic cancer
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
The First FDA-Approved Antibody-Drug Conjugate
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology